Mitral Valve Prolapse (MVP) is a prevalent cardiovascular condition characterized by an abnormal closure of the mitral valve, the valve situated between the heart's left atrium and ventricle. In MVP, the valve's leaflets exhibit an unusual bulging or backward collapse into the atrium, leading to blood regurgitation. While some individuals with MVP remain asymptomatic, others may present with symptoms such as chest discomfort, palpitations, or persistent fatigue. The precise etiology of MVP is often elusive, although it can be linked to certain connective tissue disorders. Echocardiography is the primary diagnostic tool for evaluating MVP, enabling a detailed assessment of the mitral valve's structure and functionality. Treatment is generally unnecessary for those without symptomatic manifestations, but individuals with severe cases might be advised to undergo medication therapy. In rare instances, surgical intervention may be considered to repair or replace the affected valve. Regular monitoring and consistent communication with healthcare providers are crucial for the effective management of Mitral Valve Prolapse.
Title : New mechanisms and innovative therapeutics for pulmonary hypertension
Yong Xiao Wang, Albany Medical Center, United States
Title : STEMI versus acute occlusive myocardial infarction: Which term should we use?
Yochai Birnbaum, Baylor College of Medicine, United States
Title : Beyond weight loss and diabetes control GLP 1 agonists paradigm shift in Cardiovascular care .
Syed Raza, Awali Hospital, Bahrain
Title : CARDIAC TROPONIN AND HOMOCYSTEINE LEVELS IN HEMODIALYSIS PATIENTS: ASSOCIATION WITH DIALYSIS VINTAGE AND CARDIOVASCULAR COMORBIDITY
Sofra Maria, Aretaieion University Hospital, Greece
Title : New recommendations for the prevention of sudden cardiac death in athletes and recreational sports
Sekib Sokolovic, ASA Hospital Sarajevo, Bosnia and Herzegowina
Title : Coronary revascularization in patients with diabetes: Prospects for stenting in patients with type 1 diabetes and coronary artery disease
Mekhman N Mamedov, National Research Center for Therapy and Preventive Medicine, Russian Federation